Limits...
Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project.

Frank B, Ariza L, Lamparter H, Grossmann V, Prochaska JH, Ullmann A, Kindler F, Weisser G, Walter U, Lackner KJ, Espinola-Klein C, Münzel T, Konstantinides SV, Wild PS, VTEval study gro - BMJ Open (2015)

Bottom Line: Primary short-term outcome is defined by overall mortality (PE-related death and all other causes of death), primary long-term outcome by symptomatic VTE (PE-related death, recurrence of non-fatal PE or DVT).The VTEval Project includes three 'all-comer' studies and involves the standardised acquisition of high-quality data, covering the systematic assessment of VTE including symptoms, risk profile, psychosocial, environmental and lifestyle factors as well as clinical and subclinical disease, and it builds up a large state-of-the-art biorepository containing various materials from serial blood samplings.The VTEval Project has been approved by the local data safety commissioner and the responsible ethics committee (reference no. 837.320.12 (8421-F)).

View Article: PubMed Central - PubMed

Affiliation: Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany.

No MeSH data available.


Related in: MedlinePlus

Flow chart of the VTEval Project.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499722&req=5

BMJOPEN2015008157F2: Flow chart of the VTEval Project.

Mentions: The general study flow is depicted in figure 2. Study documents have been approved by the local data safety commissioner and the responsible ethics committee (reference no. 837.320.12 (8421-F)). The studies were registered at ClinicalTrials.gov (unique identifier NCT02 156 401).


Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project.

Frank B, Ariza L, Lamparter H, Grossmann V, Prochaska JH, Ullmann A, Kindler F, Weisser G, Walter U, Lackner KJ, Espinola-Klein C, Münzel T, Konstantinides SV, Wild PS, VTEval study gro - BMJ Open (2015)

Flow chart of the VTEval Project.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499722&req=5

BMJOPEN2015008157F2: Flow chart of the VTEval Project.
Mentions: The general study flow is depicted in figure 2. Study documents have been approved by the local data safety commissioner and the responsible ethics committee (reference no. 837.320.12 (8421-F)). The studies were registered at ClinicalTrials.gov (unique identifier NCT02 156 401).

Bottom Line: Primary short-term outcome is defined by overall mortality (PE-related death and all other causes of death), primary long-term outcome by symptomatic VTE (PE-related death, recurrence of non-fatal PE or DVT).The VTEval Project includes three 'all-comer' studies and involves the standardised acquisition of high-quality data, covering the systematic assessment of VTE including symptoms, risk profile, psychosocial, environmental and lifestyle factors as well as clinical and subclinical disease, and it builds up a large state-of-the-art biorepository containing various materials from serial blood samplings.The VTEval Project has been approved by the local data safety commissioner and the responsible ethics committee (reference no. 837.320.12 (8421-F)).

View Article: PubMed Central - PubMed

Affiliation: Center for Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany.

No MeSH data available.


Related in: MedlinePlus